This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. So what does the game look like to a late-stage investor or a pharmacompany head of R&D thinking about portfolio prioritisation?
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharmacompanies have the most supplementary protection certificates?
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharmacompanies have the most supplementary protection certificates?
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharmacompanies have the most supplementary protection certificates?
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharmacompanies have the most supplementary protection certificates?
Pharmaceuticalcompanies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) covers the current state of the pharmaceutical manufacturing and packaging industry. The Congress gathers pharmaceuticalcompanies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies.
Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.
Over the next few years, the practice of asset-centric investing was honed through various iterations all designed to counter the inherent progression bias that damages returns in pharmaceutical R&D. Doing that allowed the creation of new tools that are appropriate to deploy much later in the pharmaceutical R&D process.
Swiss pharmacompany to acquire biotech for $449m (€380m).
Swiss pharmacompany Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m).
The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharmacompanies were the originators in only 28% of approvals[4].
.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., Vickers has over 30 years of experience as a researcher and leader in the pharmaceutical industry.
The free event, hosted by OVID Health, follows the success of the inaugural Patient Partnership Index, which saw four pharmacompanies achieve GOLD standard for their entries. Places are limited, with priority being given to those working for pharmaceuticalcompanies or patient groups.
Omnichannel engagement for physician marketing is a powerful tool for biotechnology and pharmacompanies looking to increase reach and drive engagement among HCPs. By taking a tailored approach, pharmacompanies can ensure they’re offering meaningful information that resonates with each individual HCP.
It is reported that every one of the major pharmaceuticalcompanies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? 36 PharmaCompanies Using Artificial Intelligence in Drug Discovery.” Nature , vol. RARE Facts.”
At the beginning of 2023, the PPD clinical research business of Thermo Fisher Scientific surveyed 120 drug developers across the pharmaceutical, biopharmaceutical and biotechnology sectors (referred to collectively as “pharma”) to learn more about sponsors’ current needs for site and patient recruitment services.
Cultural differences between the UK and mainland Europe were still quite different then but we settled in Southampton and I later went to University in Brighton, studied for a D.Phil, and found a job at a Pharmacompany. How important is it to have role models for young women working in the pharmaceutical industry?
I worked on a project that required development of a highly sensitive method and analysis of an active pharmaceutical ingredient to determine accurate levels of two potential genotoxic impurities. We are responsible for formulating a long-term strategy for addressing nitrosamine impurities in pharmaceuticals.
Khinast. GRAZ, AUSTRIA, October 30, 2020 /24-7PressRelease/ — The Research Center Pharmaceutical Engineering GmbH (RCPE), a global leader in pharmaceutical engineering sciences, has been awarded FDA funding for two projects commencing in the 4th quarter of 2020. ” Prof.
This effort seeks to provide the pharmaceutical industry with more accurate representation of patient populations, thereby enhancing the safety and efficacy for prescription drugs and medical devices. Hence, pharmaceuticalcompanies need to start making preparations to ensure compliance with the new requirements.
Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. We also have collaborations with pharmaceuticalcompanies where we leverage the best of our unique platform and pharma expertise on the target.
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceuticalcompanies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.
As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceuticalcompanies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist. Why This is a Fail.
The availability of new analytics tools and the expansion of data sources has led many pharmacompanies to adopt a data-driven approach to decision-making during the early stages of the clinical trial planning process. Accelerating your clinical trial supply through digitalization.
Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.
Find out below how Thermo Fisher Scientific and the University of Oxford are working together to combat the Covid-19 pandemic and discover how pharmaceutical logistics companies are preparing for vaccine distribution. Thermo Fisher Scientific gains CE Mark Certification for its Covid-19 test.
Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharmacompany or assume a role on one or more boards of directors. Rothenberg took over as Pfizer CMO in January 2019, but spent more than 12 years in total working for the pharmaceutical giant.
Following clinical practice, I transitioned to the world of pharmaceuticalcompanies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Being a doctor means giving courage and hope day in, day out to those experiencing illness.
A significant challenge for biotech and pharmaceuticalcompanies is to make sense of the signals coming from genome-wide association studies (GWAS), most of which are in the non-coding part of the genome. We released the package on my personal GitHub so that I could keep updating it in the future.
Connecticut-based Biohaven Pharmaceuticals was looking pretty hopeful with its third-generation prodrug to modulate glutamate, the most abundant excitatory neurotransmitter in the human body.
“Our ambition is to become the first pharmacompany powered by artificial intelligence at scale, giving our people tools and technologies that focus on insights and allow them to make better everyday decisions. … Deep Learning Deep learning, a subset of ML, employs neural networks with multiple layers to model complex patterns in data.
Drug Pricing, Global Diversity Strategies, & Emerging AI Applications Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the year ahead.
Since KOLs play such a critical role, engaging with the right KOLs is a key strategy for pharmaceuticalcompanies to stay ahead of the game. Compliance ensures that interactions between pharmaceuticalcompanies and KOLs are transparent, fair, and free from any undue influence.
Ensuring access to safe and effective treatments is the main challenge faced by pharmaceuticalcompanies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine?
Eryn has a wealth of expertise in diverse therapeutic areas and, after her experiences with battling cancer, a commitment to advancing the pharmaceutical industry by merging conventional and alternative treatments into one model. Get to know Eryn with this Q&A: What motivated you to pursue a doctorate degree?
That’s the part of the process that’s analgous to the library evolution phase of Galaxy The classical approach beloved of large pharmacompanies is really a brute-force method: make as many molecules as you can to assemble the SAR.
TOKYO & AUSTIN, Texas–( BUSINESS WIRE )– Taiho Pharmaceutical Co., We are honored to partner with Taiho, a Japanese pharmaceuticalcompany with a commitment to the respiratory field, for the development and commercialization of LTI-01 in Japan. About Taiho Pharmaceutical Co., 12, 2020 11:00 UTC.
We had a significantly limited set of Phase 1B data in psoriasis patients for TYK2 at the time, and we were now free to speak to pharmacompanies interested in our TYK2 program. At the Board meeting in early 2022, we were scrambling. There was some interest at the time, but not resounding. The Nimbus phones lit up.
Scientists and, increasingly, biotechs and pharmacompanies hope to create a more detailed map of the surfaceome, the entire cancer cell surface and its membrane-bound proteins. Therefore, to create targeted treatments there is the need to develop novel technologies to identify targets on the surface of cancer cells. in 2019.
Because pharmacompanies can’t predict which early-stage drug candidates will succeed, they end up playing a “numbers game,” according to Bush, by advancing multiple compounds. What happens if we are able to provide information to the pharmaceuticalcompany that doubles that [and] one in 10 molecules actually make it?”
This week, another pharmacompany revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose.
Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
During his tenure, Evotec established itself as a leading drug discovery and development company with a particular focus on precision medicine through early adoption of paradigm-shifting technologies such as iPSC-based drug discovery, industrialised multi-omics, and artificial intelligence-driven data analytics throughout the drug discovery process.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content